Piermont Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Piermont Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-84,870	Closed	-$1.26M	–	126
2018 Q3	$1.26M	Sell	84,870 -6,630	-7%	-$103K	0.51%	106
2018 Q2	$1.46M	Buy	+91,500	New	+$1.36M	0.45%	103
2016 Q2	–	Sell	-118,909	Closed	-$2.45M	–	293
2016 Q1	$2.45M	Sell	118,909 -2,910	-2%	-$57.3K	0.78%	59
2015 Q4	$2.5M	Buy	+121,819	New	+$2.34M	0.79%	56

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Piermont Capital Management's VIVO Position: Q4 2018 in Review

Piermont Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2018, closing a stake of 84,870 shares — an estimated $1.26M sold.

Piermont Capital Management first reported a position in VIVO in Q4 2015 and held it in 4 quarters. The position peaked at $2.5M in Q4 2015. 191 funds tracked by Wall St. Rank hold VIVO as of Q4 2018.

Piermont Capital Management reported no remaining Meridian Bioscience Inc position as of Q4 2018 after selling out during the quarter.
Piermont Capital Management sold 84,870 Meridian Bioscience Inc shares in Q4 2018, an estimated $1.26M.
Piermont Capital Management first reported a position in Meridian Bioscience Inc in Q4 2015 and held it in 4 quarters.
Piermont Capital Management's Meridian Bioscience Inc position peaked at $2.5M in Q4 2015.
191 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2018.

Based on Piermont Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.